Literature DB >> 10844530

Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation.

M Di Renzo1, Z Zhou, I George, K Becker, C Cunningham-Rundles.   

Abstract

CVID is a primary immune disorder in which hypogammaglobulinaemia may be associated with a number of T cell defects including lymphopenia, anergy, impaired lymphocyte proliferation and deficient cytokine secretion. In this study we show that T cells of CVID subjects, in comparison with control T cells, undergo spontaneous apoptosis in culture and markedly accelerated apoptosis after gamma-irradiation. Although costimulation of the CD28 receptor following engagement of the TCR/CD3 receptor normally provides a second signal necessary for IL-2 secretion, CD28 costimulation in CVID does not significantly increase IL-2 production, nor does this combination of activators enhance the survival of irradiated CVID T cells, as it does for cultured normal T cells. Addition of IL-2 enhances CVID T cell survival, suggesting that the IL-2 signalling pathways are normal. CVID T cells have similar expression of Bcl-2 to control T cells. CD3 stimulation up-regulates T cell expression of bcl-xL mRNA for normal T cells, but anti-CD28 does not augment bcl-xL expression for CVID subjects with accelerated apoptosis. Defects of the CD28 receptor pathway, leading to cytokine deprivation and dysregulation of bcl-xL, could lead to poor T cell viability and some of the cellular defects observed in CVID.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844530      PMCID: PMC1905559          DOI: 10.1046/j.1365-2249.2000.01239.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.

Authors:  C D Gimmi; G J Freeman; J G Gribben; K Sugita; A S Freedman; C Morimoto; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

2.  IL-2 protects against anti-CD3-induced cell death in human medullary thymocytes.

Authors:  M A Nieto; A González; A López-Rivas; F Diaz-Espada; F Gambón
Journal:  J Immunol       Date:  1990-09-01       Impact factor: 5.422

3.  Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency.

Authors:  M C Sneller; W Strober
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

4.  Defective DNA synthesis by T cells in acquired 'common-variable' hypogammaglobulinaemia on stimulation with mitogens.

Authors:  M E North; G P Spickett; J Allsop; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2.

Authors:  A Bryant; N C Calver; E Toubi; A D Webster; J Farrant
Journal:  Clin Immunol Immunopathol       Date:  1990-08

6.  Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features.

Authors:  J J Wright; D K Wagner; R M Blaese; C Hagengruber; T A Waldmann; T A Fleisher
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

7.  Peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) produce reduced levels of interleukin-4, interleukin-2 and interferon-gamma, but proliferate normally upon activation by mitogens.

Authors:  G Pastorelli; M G Roncarolo; J L Touraine; G Peronne; P A Tovo; J E de Vries
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

8.  Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28.

Authors:  J D Fraser; B A Irving; G R Crabtree; A Weiss
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

9.  Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency.

Authors:  G Kruger; K Welte; N Ciobanu; C Cunningham-Rundles; P Ralph; S Venuta; S Feldman; B Koziner; C Y Wang; M A Moore
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

10.  Three distinct stages of B-cell defects in common varied immunodeficiency.

Authors:  O Saiki; P Ralph; C Cunningham-Rundles; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  14 in total

1.  Enhanced T cell apoptosis in common variable immunodeficiency: negative role of the fas/fasligand system and of the Bcl-2 family proteins and possible role of TNF-RS.

Authors:  M Di Renzo; D Serrano; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

2.  CTLA-4 gene exon-1 +49 A/G polymorphism: lack of association with autoimmune disease in patients with common variable immune deficiency.

Authors:  Adina Kay Knight; Davide Serrano; Yaron Tomer; Charlotte Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

3.  T-cell response to viral antigens in adults and children with common variable immunodeficiency and specific antibody deficiency.

Authors:  L M Haveman; J Scherrenburg; L J Maarschalk-Ellerbroek; P D Hoek; R Schuurman; W de Jager; P M Ellerbroek; B J Prakken; D van Baarle; J M van Montfrans
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

4.  Characterization of Herpesvirus saimiri-transformed T lymphocytes from common variable immunodeficiency patients.

Authors:  J A Cabanillas; R Cambronero; A Pacheco-Castro; M C García-Rodríguez; J M Martín-Fernández; G Fontán; J R Regueiro
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 5.  Common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

6.  Linkage of autosomal dominant common variable immunodeficiency to chromosome 5p and evidence for locus heterogeneity.

Authors:  D U Braig; A A Schäffer; E Glocker; U Salzer; K Warnatz; H H Peter; B Grimbacher
Journal:  Hum Genet       Date:  2003-02-06       Impact factor: 4.132

7.  Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency.

Authors:  Asghar Aghamohammadi; Hirokazu Kanegane; Mostafa Moein; Abolhasan Farhoudi; Zahra Pourpak; Masoud Movahedi; Mohammad Gharagozlou; Ali Akabar Amir Zargar; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

8.  Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications.

Authors:  Nima Rezaei; Mostafa Haji-Molla-Hoseini; Asghar Aghamohammadi; Ali Akbar Pourfathollah; Mina Moghtadaie; Zahra Pourpak
Journal:  J Clin Immunol       Date:  2007-10-03       Impact factor: 8.317

9.  In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency.

Authors:  Hasibe Artac; Reyhan Kara; Ismail Reisli
Journal:  Clin Exp Med       Date:  2010-03       Impact factor: 3.984

Review 10.  Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge.

Authors:  Farnaz Najmi Varzaneh; Bärbel Keller; Susanne Unger; Asghar Aghamohammadi; Klaus Warnatz; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05-15       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.